Recent Updates
Recently added Catalysts
TLPH Positive Sentiment

Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

Key Takeaway: Talphera, Inc. will host a conference call on November 12, 2026, to discuss its third-quarter financial results and recent business developments. The call will take place at 4:30 PM ET. The company is focused on developing therapies for medically supervised settings, with its lead product Niyad® under investigation as an anticoagulant.

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera will report Q3 financial results soon.
  • The company is focused on innovative therapies.
  • Niyad® has received Breakthrough Device Designation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~10 mo
Medium dilution risk
Lead asset
Sufentanil/Triazolam NanoTab
Phase 3 · Acute Moderate-to-severe Pain

Full Press Release Details

SAN MATEO, Calif., Nov. 4, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the third quarter ended September 30, 2026 and recent business progress.

Conference Call and Webcast Information

• Date: Thursday, November 12, 2026 at 4:30 PM ET/1:30 PM PT
• Participant Dial-in (North America): 1-800-836-8184
• Participant Dial-in (International): 1-646-357-8785
• Conference ID: 69368
• Webcast Access: Click here
The event can also be accessed in the Upcoming Events page in the Investors section of the Talphera website at www.talphera.com.
A replay of the webcast will be available on the Talphera website for 90 days after the event.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Frequently Asked Questions

When will Talphera report its Q3 2026 results?

Talphera will report its Q3 2026 results on November 12, 2026.

What time is the conference call for Q3 results?

The conference call is scheduled for 4:30 PM ET.

How can I access the conference call?

You can access the call via dial-in or webcast on Talphera's website.

What is Talphera's lead product candidate?

Talphera's lead product candidate is Niyad®, an anticoagulant.

Last updated: Nov 4, 2026